Document: Barr Responses To QFR’s: CLR Digs Out The Relevant Q’s & A’s
Cannabis Law Report
JANUARY 30, 2019
I support the expansion of marijuana manufacturers for scientific research consistent with law. While this is a positive step and will provide a new treatment option for those with two types of intractable epilepsy, it is my understanding that this scheduling action relates only to CBD in an FDA-approved formulation. R ESPONSE: Yes.
63 
Let's personalize your content